Evidence map›Paper›PMID 39062492›Full record

ArticleBiomolecules2024

COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy.

Mariana Bondrescu, Liana Dehelean, Simona Sorina Farcas, Ion Papava, Vlad Nicoras, Dana Violeta Mager, Anca Eliza Grecescu, Petre Adrian Podaru, Nicoleta Ioana Andreescu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mariana BondrescuDepartment of Neurosciences-Psychiatry, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania.ORCID 0000-0003-0852-3503
Liana DeheleanDepartment of Neurosciences-Psychiatry, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
Simona Sorina FarcasDiscipline of Medical Genetics, Department of Microscopic Morphology, Center of Genomic Medicine "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
Ion PapavaDepartment of Neurosciences-Psychiatry, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania.ORCID 0000-0003-0963-8222
Vlad NicorasTimis County Emergency Clinical Hospital "Pius Brinzeu", Liviu Rebreanu 156, 300723 Timisoara, Romania.
Dana Violeta MagerTimis County Emergency Clinical Hospital "Pius Brinzeu", Liviu Rebreanu 156, 300723 Timisoara, Romania.
Anca Eliza GrecescuTimis County Emergency Clinical Hospital "Pius Brinzeu", Liviu Rebreanu 156, 300723 Timisoara, Romania.
Petre Adrian PodaruFaculty of Mathematics and Informatics, West University of Timisoara, Vasile Parvan 4, 300223 Timisoara, Romania.
Nicoleta Ioana AndreescuDiscipline of Medical Genetics, Department of Microscopic Morphology, Center of Genomic Medicine "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania.ORCID 0000-0002-2647-4234

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacogenetic markers are current targets for the personalized treatment of psychosis. Limited data exist on COMT and NRG1 polymorphisms in relation to risperidone treatment. This study focuses on the impact of COMT rs4680 and NRG1 (rs35753505, rs3924999) polymorphisms on risperidone treatment in schizophrenia spectrum disorders (SSDs). This study included 103 subjects with SSD treated with risperidone monotherapy. COMT rs4680, NRG1 rs35753505, and rs3924999 were analyzed by RT-PCR. Participants were evaluated via the Positive and Negative Syndrome Scale (PANSS) after six weeks. Socio-demographic and clinical characteristics were collected. COMT rs4680 genotypes significantly differed in PANSS N scores at admission: AG>AA genotypes (

Indexed as

Antipsychotic AgentsCatechol O-MethyltransferaseNeuregulin-1Polymorphism, Single NucleotideRisperidoneSchizophreniaAdultFemaleGenotypeHumansMaleMiddle AgedPrecision MedicineAntipsychotic AgentsCatechol O-MethyltransferaseCOMT protein, humanNeuregulin-1NRG1 protein, humanRisperidoneCOMTneuregulin 1risperidone monotherapyschizophrenia spectrum disorders

Identifiers

PMID39062492
PMCPMC11275090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.